UTI Differential Diagnosis in Females: A Comprehensive Guide for Automotive Experts

Introduction

Uncomplicated urinary tract infections (UTIs) are a prevalent health concern, particularly among women. As experts in automotive repair at xentrydiagnosis.store, understanding the complexities of diagnostic processes, even in seemingly unrelated fields, can enhance problem-solving skills and attention to detail. This article delves into the differential diagnosis of UTIs in females, a crucial aspect of healthcare, mirroring the systematic diagnostic approaches we apply to vehicle issues. While our primary focus remains automotive diagnostics, exploring medical diagnostic frameworks like UTI differential diagnosis can broaden our analytical perspectives.

Uncomplicated UTIs, primarily affecting the bladder (cystitis), are bacterial infections in otherwise healthy women without urinary tract abnormalities or significant comorbidities. Symptoms such as urinary frequency, urgency, dysuria, and suprapubic discomfort are common. Although many UTIs resolve spontaneously, treatment is often sought for symptom relief and to prevent complications such as pyelonephritis. Accurate and timely diagnosis is paramount. This discussion will explore the clinical presentation, diagnostic evaluation, and, importantly, the Uti Differential Diagnosis Female, ensuring a comprehensive understanding for improved patient care in medical settings.

Etiology and Risk Factors in Women

The female anatomy predisposes women to UTIs due to the shorter urethra and proximity of the perineum and rectum to the periurethral area, facilitating bacterial ascent. While Escherichia coli is the predominant pathogen, Klebsiella, Proteus, Enterobacter, and Enterococcus are also significant.

Risk factors in women include:

Abnormal urination patterns (incomplete emptying)
Anatomical or functional urinary tract abnormalities
Antibiotic use and subsequent bacterial resistance
Cystocele
Dehydration
Diabetes mellitus
Diarrhea
Early age of first UTI (before 15 years)
Frequent pelvic exams
Immunosuppression
Irritable bowel syndrome
Menopause
Maternal history of recurrent UTIs
New or multiple sexual partners
Poor hygiene
Pregnancy
Sexual intercourse
Urinary tract calculi
Spermicide and diaphragm use

Image alt text: A close-up view of a urinalysis dipstick test showing positive results for leukocyte esterase and nitrites, indicators suggestive of a urinary tract infection (UTI).

Epidemiology in Females

UTIs are significantly more common in females, occurring at least four times more frequently than in males. Statistics highlight the prevalence:

Approximately 40% of women will experience a UTI in their lifetime.
Around 10% of women experience a UTI annually.
Recurrence is frequent, with nearly half of affected women experiencing a second infection within a year.
UTIs are most common in women aged 16 to 35.

Pathophysiology of Uncomplicated UTIs in Women

Uncomplicated UTIs primarily involve the bladder. Uropathogens, often enteric coliforms residing in the periurethral vaginal area, ascend the urethra and invade the bladder mucosa. This invasion triggers cystitis, an inflammatory response. Sexual intercourse is a recognized factor in UTI development due to bacterial inoculation into the bladder.

The urinary environment possesses natural antimicrobial properties, including acidic pH, high urea concentrations, and inhibitory proteins. Frequent urination further reduces UTI risk. The bladder’s mucosal lining provides a protective barrier against bacterial invasion. Urothelial cells contribute to defense by producing antimicrobial peptides and cytokines, and by shedding infected superficial layers. In premenopausal women, vaginal lactobacilli and acidic pH prevent uropathogen colonization, a balance that can be disrupted by antibiotic use. Uropathogenic bacteria often possess adhesins, facilitating mucosal attachment and survival in the urinary environment.

History and Physical Examination in Female UTI Diagnosis

Typical symptoms of uncomplicated UTIs in women include dysuria, urinary frequency and urgency, hesitancy, suprapubic pain, bladder spasms, and hematuria. Systemic symptoms like fever, chills, nausea, vomiting, or flank pain are less common and suggest potential pyelonephritis or a more complicated infection. However, symptom overlap can occur, and aggressive treatment for potential upper tract involvement is advised when diagnostic uncertainty exists. Medical history, including prior antibiotic use and UTI history, is essential.

Physical examination findings are often unremarkable in uncomplicated UTIs, although suprapubic tenderness may be present. Pelvic exams are indicated in cases of recurrent UTIs, incontinence, or suspected pelvic organ prolapse. Diagnosis relies on a combination of symptoms, urinalysis, and urine culture. It’s crucial to avoid diagnosing UTIs solely based on urinalysis or culture in asymptomatic patients. Cloudy or odorous urine alone is insufficient for UTI diagnosis requiring antibiotics unless accompanied by other UTI signs and symptoms.

In older women, altered mental status or behavioral changes may be the primary UTI indicators, alongside abnormal urinalysis and dysuria. Spinal cord-injured patients may present with autonomic dysreflexia, chills, fever, spasticity changes, or fatigue. Patients with indwelling catheters often exhibit pyuria and bacteriuria, which do not necessitate treatment unless systemic symptoms are present.

Evaluation and Diagnostic Testing for UTI in Women

Urine Specimen Collection

Proper urine collection is critical for accurate UTI diagnosis. Clean-catch midstream specimens are preferred, requiring thorough handwashing and proper technique, especially in non-obese women. Obese women may require catheterized specimens to minimize contamination. Men should cleanse the glans before collection. Pediatric and spinal cord-injured patients might necessitate suprapubic aspiration. Catheterized patients require specimen collection from a newly placed catheter, never from a drainage bag. Immediate lab processing or refrigeration is essential to prevent bacterial overgrowth and inaccurate results.

Urinalysis

Visual urine inspection alone is insufficient for UTI diagnosis. Dipstick testing is a rapid, clinic-based method. Key dipstick indicators include pH, nitrites, leukocyte esterase, and blood. A negative dipstick does not rule out UTI in symptomatic patients, but positive findings are suggestive. Microscopic urinalysis confirms bacteria and/or white blood cells (WBCs).

Nitrite test: Highly specific (>90%), directly indicating bacteriuria by detecting nitrite conversion from nitrates by bacteria. First-morning urine is preferred, especially in males, for optimal nitrite conversion time (6 hours). Sensitivity ranges from 19% to 48%, specificity from 92% to 100%.
Hematuria: Suggestive of UTI, helping differentiate from vaginitis or urethritis, which typically lack hematuria.

Positive nitrite and leukocyte esterase tests have high positive (85%) and negative predictive values (92%). Microscopy revealing bacteria or >10 WBC/HPF in symptomatic patients strongly suggests UTI.

Urine Culture

Urine cultures are not always needed for uncomplicated UTIs but are recommended due to increasing antibiotic resistance and to distinguish recurrent from relapsing infections. Cultures are crucial for men, diabetics, immunocompromised individuals, and pregnant women. Traditional UTI diagnosis requires >100,000 CFU/mL, but current guidelines recognize >1,000 CFU/mL in symptomatic patients as diagnostic. Cultures guide treatment, especially if empiric therapy fails, and are highly recommended by many experts for all presumed UTIs. Cystoscopy and imaging are generally not indicated for uncomplicated UTIs but may be considered for relapsing infections.

Image alt text: A petri dish displaying a urine culture test, with visible bacterial colonies indicating a positive result for urinary tract infection (UTI).

Treatment and Management of Uncomplicated UTIs in Women

Asymptomatic bacteriuria, except in pregnant, immunosuppressed, transplant recipients, or those undergoing urologic procedures, does not require treatment. Antibiotic therapy for uncomplicated UTIs has evolved to short courses, with 3-day regimens proving highly effective. Local E. coli resistance patterns dictate antibiotic choices; resistance rates exceeding 50% necessitate alternative agents.

First-line antibiotics include nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin, and first-generation cephalosporins. Pivmecillinam is a first-line agent outside the US.

Trimethoprim-sulfamethoxazole: Effective 3-day therapy, but resistance is increasing in many areas, contraindicated if local resistance >20% or in sulfa allergies.
First-generation cephalosporins: Suitable for 3-day therapy but overuse should be avoided to prevent resistance.
Fosfomycin: Single-dose option, convenient but potentially less effective than longer courses in symptom resolution.
Nitrofurantoin: Effective for lower UTIs, but not for pyelonephritis.

Increased hydration can promote spontaneous resolution in about 20% of women.

Management of recurrent UTIs involves hygiene optimization, urinary acidification (vitamin C), post-coital precautions, and prophylactic antibiotics or antiseptics like nitrofurantoin. Prophylactic treatment typically lasts 6 to 12 months, potentially longer. Relapsing infections require investigation for underlying sources like diverticula or stones.

Differential Diagnosis: UTI vs. Other Conditions in Women

The uti differential diagnosis female is broad and includes conditions mimicking UTI symptoms. It is crucial to differentiate UTI from other conditions to ensure appropriate management. Key differential diagnoses in women include:

Vaginitis: Inflammation of the vagina, often caused by yeast infections, bacterial vaginosis, or trichomoniasis. Symptoms can overlap with UTI, including vaginal discharge, itching, and dysuria (external dysuria). Key differentiators are vaginal discharge (typically absent in UTI), vaginal itching (less common in UTI), and absence of urinary urgency and frequency as primary symptoms. Urinalysis in vaginitis will be negative for nitrites and leukocyte esterase unless a concurrent UTI is present. Pelvic exam and vaginal discharge analysis are crucial for diagnosis.
Urethritis (Non-Infectious): Inflammation of the urethra without bacterial infection. Causes include chemical irritants (soaps, douches), trauma (sexual activity), or estrogen deficiency (atrophic urethritis in postmenopausal women). Symptoms include dysuria and urinary frequency. Differentiating points include the absence of bacteriuria and pyuria on urinalysis in non-infectious urethritis. History of irritant exposure or menopausal status can be suggestive.
Pelvic Inflammatory Disease (PID): Infection of the female reproductive organs, often sexually transmitted. PID can present with lower abdominal pain, pelvic pain, fever, abnormal vaginal discharge, and dysuria. Distinguishing features from UTI include significant pelvic pain, fever, abnormal vaginal discharge, cervical motion tenderness on pelvic exam, and potentially systemic symptoms. Urinalysis in PID alone will be negative for UTI markers unless a concurrent UTI exists.
Overactive Bladder (OAB): A condition characterized by urinary urgency, frequency, and nocturia, with or without urge incontinence, in the absence of UTI or other identifiable pathology. OAB symptoms, particularly urgency and frequency, can mimic UTI. Key differentiators are the absence of dysuria and negative urinalysis for infection markers in OAB. OAB is a diagnosis of exclusion after ruling out UTI and other urological conditions.
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): Chronic bladder condition characterized by pelvic pain, pressure, or discomfort perceived to be related to the bladder, accompanied by lower urinary tract symptoms like urgency and frequency, in the absence of proven infection or other obvious pathology. IC/BPS can mimic UTI symptoms, particularly chronic pelvic pain and urinary urgency/frequency. Differentiation relies on chronicity of symptoms (>6 months), pain component often being more prominent than in acute UTI, and negative urinalysis and urine culture. Cystoscopy and hydrodistention may be considered in diagnosis.
Bladder Stones and Renal Stones: Urinary calculi can cause hematuria, dysuria, and urinary urgency, mimicking UTI. Flank pain (renal stones) or suprapubic pain (bladder stones) may be more prominent. Urinalysis may show hematuria, but nitrites and leukocyte esterase may be negative unless a secondary infection is present. Imaging studies (CT scan, ultrasound) are diagnostic.
Sexually Transmitted Infections (STIs): Chlamydia and gonorrhea can cause urethritis and cervicitis in women, presenting with dysuria, urinary frequency, and vaginal discharge. While they can cause pyuria, they are not typical UTI pathogens. History of sexual activity, vaginal discharge, and STI testing are crucial for differentiation.
Herpes Simplex Virus (HSV): Genital herpes can cause painful genital lesions and dysuria. Urinary symptoms may accompany the characteristic vesicular lesions. Viral culture or PCR testing of lesions confirms HSV.
Medication Effects and Dietary Factors: Certain medications and dietary irritants can cause urinary symptoms. Reviewing medication lists and dietary history is important.
Pelvic Organ Prolapse: Cystocele or uterine prolapse can cause incomplete bladder emptying and urinary symptoms, sometimes mimicking UTI. Pelvic exam can identify prolapse.

Table: Differential Diagnosis of UTI in Females

Condition	Key Symptoms	Differentiating Features	Urinalysis	Diagnostic Tests
Uncomplicated UTI	Dysuria, frequency, urgency, suprapubic discomfort	Positive nitrite/leukocyte esterase on urinalysis, bacteriuria	Positive nitrites, leukocyte esterase, +/- hematuria	Urine culture
Vaginitis	Vaginal discharge, itching, external dysuria	Vaginal discharge, vaginal itching, absence of urinary urgency	Negative for nitrites and leukocyte esterase (unless co-UTI)	Pelvic exam, vaginal discharge microscopy/culture
Urethritis (Non-Infectious)	Dysuria, frequency	History of irritants, estrogen deficiency, negative urine culture	Negative for nitrites and leukocyte esterase	History, pelvic exam, rule out infection
Pelvic Inflammatory Disease	Pelvic pain, fever, abnormal vaginal discharge, dysuria	Pelvic pain, fever, cervical motion tenderness, systemic symptoms	Negative for nitrites and leukocyte esterase (unless co-UTI)	Pelvic exam, STI testing, pelvic ultrasound
Overactive Bladder	Urgency, frequency, nocturia	Absence of dysuria, negative urinalysis for infection markers	Negative for nitrites and leukocyte esterase	Clinical diagnosis, rule out other causes
IC/BPS	Chronic pelvic pain, urgency, frequency	Chronic symptoms, pain component, negative urine culture	Negative for nitrites and leukocyte esterase	Clinical diagnosis, cystoscopy (optional)
Urinary Stones	Hematuria, dysuria, urgency, flank/suprapubic pain	Hematuria, pain location, may lack infection signs	+/- Hematuria, negative nitrites/leukocyte esterase (unless co-UTI)	Imaging (CT, ultrasound)
STIs (Chlamydia, Gonorrhea)	Dysuria, frequency, vaginal discharge	Vaginal discharge, sexual history	May have pyuria, negative nitrites	STI testing
Genital Herpes	Dysuria, genital lesions	Painful vesicular lesions	Negative for nitrites and leukocyte esterase	Viral culture/PCR of lesions

Prognosis and Complications

The prognosis for uncomplicated UTIs in women is excellent with appropriate treatment. Symptom duration typically resolves within 2 to 4 days with antibiotics. However, recurrence is common. Morbidity is higher in older, debilitated patients or those with comorbidities. Mortality is rare in uncomplicated UTIs.

Complications, though infrequent in uncomplicated cases, include recurrent UTIs, pyelonephritis, renal abscess, and, in rare cases, more severe conditions like emphysematous pyelonephritis.

Deterrence and Patient Education

Patient education is crucial for UTI prevention and recurrence reduction. Key preventative strategies include:

Increased fluid intake.
Proper hygiene practices: wiping front to back after urination, showering over baths, using gentle, fragrance-free liquid soaps, and washing the vaginal area first during bathing.
Urinating after sexual intercourse.
Avoiding spermicides and diaphragms if prone to UTIs.
Considering non-antibiotic options like cranberry products, D-mannose, methenamine, or probiotics, although evidence varies.

Enhancing Healthcare Team Outcomes

Effective UTI management requires an interprofessional team approach. Nurses play a vital role in patient education. Pharmacists and infectious disease specialists ensure optimal antibiotic selection and dosing. Close collaboration and communication among healthcare team members improve patient outcomes and reduce UTI recurrence.

Conclusion

Understanding the uti differential diagnosis female is essential for accurate diagnosis and management in healthcare settings. By considering the various conditions that mimic UTI, clinicians can provide targeted and effective care, improving patient outcomes and reducing unnecessary antibiotic use. While our expertise at xentrydiagnosis.store lies in automotive diagnostics, appreciating the systematic approach to medical diagnoses, like UTI differential diagnosis, reinforces our commitment to thorough and precise problem-solving in all domains.

References

[List of references from the original article, ensuring they are correctly formatted and linked]

(Note: The references are directly copied from the original article to maintain accuracy and completeness as per instructions.)

1.Sabih A, Leslie SW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 12, 2023. Complicated Urinary Tract Infections. PubMed: 28613784

2.Five-day nitrofurantoin is better than single-dose fosfomycin at resolving UTI symptoms. Drug Ther Bull. 2018 Nov;56(11):131. PubMed: 30297448

3.Long B, Koyfman A. The Emergency Department Diagnosis and Management of Urinary Tract Infection. Emerg Med Clin North Am. 2018 Nov;36(4):685-710. PubMed: 30296999

4.Tang M, Quanstrom K, Jin C, Suskind AM. Recurrent Urinary Tract Infections are Associated With Frailty in Older Adults. Urology. 2019 Jan;123:24-27. PMC free article: PMC8528015 PubMed: 30296501

5.Aggarwal N, Leslie SW, Lotfollahzadeh S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 2, 2024. Recurrent Urinary Tract Infections. PMC free article: PMC557479 PubMed: 32491411

6.Behzadi P, Behzadi E, Yazdanbod H, Aghapour R, Akbari Cheshmeh M, Salehian Omran D. A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Maedica (Bucur). 2010 Apr;5(2):111-5. PMC free article: PMC3150015 PubMed: 21977133

7.Yamaji R, Friedman CR, Rubin J, Suh J, Thys E, McDermott P, Hung-Fan M, Riley LW. A Population-Based Surveillance Study of Shared Genotypes of Escherichia coli Isolates from Retail Meat and Suspected Cases of Urinary Tract Infections. mSphere. 2018 Aug 15;3(4) PMC free article: PMC6094058 PubMed: 30111626

8.Li R, Leslie SW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 30, 2023. Cystitis. PubMed: 29494042

9.Leung AKC, Wong AHC, Leung AAM, Hon KL. Urinary Tract Infection in Children. Recent Pat Inflamm Allergy Drug Discov. 2019;13(1):2-18. PMC free article: PMC6751349 PubMed: 30592257

10.May M, Schostak M, Lebentrau S., MR2- study group. Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine. Int Urogynecol J. 2019 Feb;30(2):335-336. PubMed: 30564871

11.Lala V, Leslie SW, Minter DA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 10, 2023. Acute Cystitis. PubMed: 29083726

12.Sakamoto S, Miyazawa K, Yasui T, Iguchi T, Fujita M, Nishimatsu H, Masaki T, Hasegawa T, Hibi H, Arakawa T, Ando R, Kato Y, Ishito N, Yamaguchi S, Takazawa R, Tsujihata M, Taguchi M, Akakura K, Hata A, Ichikawa T. Chronological changes in epidemiological characteristics of lower urinary tract urolithiasis in Japan. Int J Urol. 2019 Jan;26(1):96-101. PubMed: 30308705

13.Alperin M, Burnett L, Lukacz E, Brubaker L. The mysteries of menopause and urogynecologic health: clinical and scientific gaps. Menopause. 2019 Jan;26(1):103-111. PMC free article: PMC6376984 PubMed: 30300297

14.Maharjan G, Khadka P, Siddhi Shilpakar G, Chapagain G, Dhungana GR. Catheter-Associated Urinary Tract Infection and Obstinate Biofilm Producers. Can J Infect Dis Med Microbiol. 2018;2018:7624857. PMC free article: PMC6129315 PubMed: 30224941

15.Sobel JD. New aspects of pathogenesis of lower urinary tract infections. Urology. 1985 Nov;26(5 Suppl):11-6. PubMed: 3904135

16.Ipe DS, Horton E, Ulett GC. The Basics of Bacteriuria: Strategies of Microbes for Persistence in Urine. Front Cell Infect Microbiol. 2016;6:14. PMC free article: PMC4744864 PubMed: 26904513

17.Chambers ST, Lever M. Betaines and urinary tract infections. Nephron. 1996;74(1):1-10. PubMed: 8883013

18.Kucheria R, Dasgupta P, Sacks SH, Khan MS, Sheerin NS. Urinary tract infections: new insights into a common problem. Postgrad Med J. 2005 Feb;81(952):83-6. PMC free article: PMC1743204 PubMed: 15701738

19.Carlsson S, Wiklund NP, Engstrand L, Weitzberg E, Lundberg JO. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide. 2001 Dec;5(6):580-6. PubMed: 11730365

20.Cornish J, Lecamwasam JP, Harrison G, Vanderwee MA, Miller TE. Host defence mechanisms in the bladder. II. Disruption of the layer of mucus. Br J Exp Pathol. 1988 Dec;69(6):759-70. PMC free article: PMC2013295 PubMed: 3064799

21.Abraham SN, Miao Y. The nature of immune responses to urinary tract infections. Nat Rev Immunol. 2015 Oct;15(10):655-63. PMC free article: PMC4926313 PubMed: 26388331

22.Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC, Heuser J, Hultgren SJ. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science. 1998 Nov 20;282(5393):1494-7. PubMed: 9822381

23.Hudson PL, Hung KJ, Bergerat A, Mitchell C. Effect of Vaginal Lactobacillus Species on Escherichia coli Growth. Female Pelvic Med Reconstr Surg. 2020 Feb;26(2):146-151. PubMed: 31990804

24.Bunduki GK, Heinz E, Phiri VS, Noah P, Feasey N, Musaya J. Virulence factors and antimicrobial resistance of uropathogenic Escherichia coli (UPEC) isolated from urinary tract infections: a systematic review and meta-analysis. BMC Infect Dis. 2021 Aug 04;21(1):753. PMC free article: PMC8336361 PubMed: 34348646

25.Paudel S, John PP, Poorbaghi SL, Randis TM, Kulkarni R. Systematic Review of Literature Examining Bacterial Urinary Tract Infections in Diabetes. J Diabetes Res. 2022;2022:3588297. PMC free article: PMC9130015 PubMed: 35620571

26.Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, Tinetti M. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc. 2009 Jun;57(6):963-70. PMC free article: PMC2692075 PubMed: 19490243

27.Juthani-Mehta M, Tinetti M, Perrelli E, Towle V, Van Ness PH, Quagliarello V. Interobserver variability in the assessment of clinical criteria for suspected urinary tract infection in nursing home residents. Infect Control Hosp Epidemiol. 2008 May;29(5):446-9. PMC free article: PMC2671070 PubMed: 18419369

28.Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014 Feb 26;311(8):844-54. PMC free article: PMC4194886 PubMed: 24570248

29.Allen KJ, Leslie SW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 30, 2023. Autonomic Dysreflexia. PubMed: 29494041

30.Richards KA, Cesario S, Best SL, Deeren SM, Bushman W, Safdar N. Reflex urine culture testing in an ambulatory urology clinic: Implications for antibiotic stewardship in urology. Int J Urol. 2019 Jan;26(1):69-74. PubMed: 30221416

31.Araujo da Silva AR, Marques AF, Biscaia di Biase C, Zingg W, Dramowski A, Sharland M. Interventions to prevent urinary catheter-associated infections in children and neonates: a systematic review. J Pediatr Urol. 2018 Dec;14(6):556.e1-556.e9. PubMed: 30126746

32.Karki N, Leslie SW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 30, 2023. Struvite and Triple Phosphate Renal Calculi. PubMed: 33760542

33.Suresh J, Krishnamurthy S, Mandal J, Mondal N, Sivamurukan P. Diagnostic Accuracy of Point-of-care Nitrite and Leukocyte Esterase Dipstick Test for the Screening of Pediatric Urinary Tract Infections. Saudi J Kidney Dis Transpl. 2021 May-Jun;32(3):703-710. PubMed: 35102912

34.Chernaya A, Søborg C, Midttun M. Validity of the urinary dipstick test in the diagnosis of urinary tract infections in adults. Dan Med J. 2021 Dec 15;69(1) PubMed: 34913433

35.Malia L, Strumph K, Smith S, Brancato J, Johnson ST, Chicaiza H. Fast and Sensitive: Automated Point-of-Care Urine Dips. Pediatr Emerg Care. 2020 Oct;36(10):486-488. PubMed: 29189595

36.Bellazreg F, Abid M, Lasfar NB, Hattab Z, Hachfi W, Letaief A. Diagnostic value of dipstick test in adult symptomatic urinary tract infections: results of a cross-sectional Tunisian study. Pan Afr Med J. 2019;33:131. PMC free article: PMC6754830 PubMed: 31558930

37.Little P, Turner S, Rumsby K, Warner G, Moore M, Lowes JA, Smith H, Hawke C, Turner D, Leydon GM, Arscott A, Mullee M. Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health Technol Assess. 2009 Mar;13(19):iii-iv, ix-xi, 1-73. PubMed: 19364448

38.Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004 Apr 15;38(8):1150-8. PubMed: 15095222

39.Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ, Hickling D, Kapoor A, Kenton KS, Kaufman MR, Rondanina MA, Stapleton A, Stothers L, Chai TC. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol. 2019 Aug;202(2):282-289. PubMed: 31042112

40.Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am. 2003 Jun;17(2):243-59. PubMed: 12848469

41.Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, Lavi I, Stamm W., Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002 May 01;34(9):1165-9. PubMed: 11941541

42.Stein GE. Single-dose treatment of acute cystitis with fosfomycin tromethamine. Ann Pharmacother. 1998 Feb;32(2):215-9. PubMed: 9496408

43.Tutone M, Bjerklund Johansen TE, Cai T, Mushtaq S, Livermore DM. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study. Int J Antimicrob Agents. 2022 May;59(5):106574. PubMed: 35307561

44.Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. [Efficiency of fosfomycin trometamol for treatment of acute uncomplicated cystitis]. Urologiia. 2018 Dec;(6):70-75. PubMed: 30742381

45.Jo JK, Kim DS, Sim Y, Ryu S, Kim KS. A Comparative Study of Urinary Tests and Cultures for the Effectiveness of Fosfomycin in Catheter-Related Urinary Tract Infections. J Clin Med. 2022 Dec 05;11(23) PMC free article: PMC9736013 PubMed: 36498803

46.O’Grady MC, Barry L, Corcoran GD, Hooton C, Sleator RD, Lucey B. Empirical treatment of urinary tract infections: how rational are our guidelines? J Antimicrob Chemother. 2019 Jan 01;74(1):214-217. PubMed: 30295780

47.Ditkoff EL, Theofanides M, Aisen CM, Kowalik CG, Cohn JA, Sui W, Rutman M, Adam RA, Dmochowski RR, Cooper KL. Assessment of practices in screening and treating women with bacteriuria. Can J Urol. 2018 Oct;25(5):9486-9496. PubMed: 30281006

48.Ganzeboom KMJ, Uijen AA, Teunissen DTAM, Assendelft WJJ, Peters HJG, Hautvast JLA, Van Jaarsveld CHM. Urine cultures and antibiotics for urinary tract infections in Dutch general practice. Prim Health Care Res Dev. 2018 Aug 31;20:e41. PMC free article: PMC6536752 PubMed: 30168406

49.Graninger W. Pivmecillinam–therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. PubMed: 14527775

50.Stair SL, Palmer CJ, Lee UJ. Evidence-based review of nonantibiotic urinary tract infection prevention strategies for women: a patient-centered approach. Curr Opin Urol. 2023 May 01;33(3):187-192. PubMed: 36862100

51.Konesan J, Liu L, Mansfield KJ. The Clinical Trial Outcomes of Cranberry, D-Mannose and NSAIDs in the Prevention or Management of Uncomplicated Urinary Tract Infections in Women: A Systematic Review. Pathogens. 2022 Dec 05;11(12) PMC free article: PMC9788503 PubMed: 36558804

52.Bakhit M, Krzyzaniak N, Hilder J, Clark J, Scott AM, Mar CD. Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. Br J Gen Pract. 2021 Jul;71(708):e528-e537. PMC free article: PMC8136580 PubMed: 34001538

53.Botros C, Lozo S, Iyer S, Warren A, Goldberg R, Tomezsko J, Sasso K, Sand P, Gafni-Kane A, Biener A, Botros-Brey S. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. Int Urogynecol J. 2022 Mar;33(3):571-580. PubMed: 34115162

54.Bartlett JE, De Bellis A. The prevention of urinary tract infections in aged care residents through the use of cranberry products: a critical analysis of the literature. Contemp Nurse. 2022 Aug;58(4):296-316. PubMed: 35861109

55.Jeitler M, Michalsen A, Schwiertz A, Kessler CS, Koppold-Liebscher D, Grasme J, Kandil FI, Steckhan N. Effects of a Supplement Containing a Cranberry Extract on Recurrent Urinary Tract Infections and Intestinal Microbiota: A Prospective, Uncontrolled Exploratory Study. J Integr Complement Med. 2022 May;28(5):399-406. PMC free article: PMC9127832 PubMed: 35285701

56.Montorsi F, Gandaglia G, Salonia A, Briganti A, Mirone V. Effectiveness of a Combination of Cranberries, Lactobacillus rhamnosus, and Vitamin C for the Management of Recurrent Urinary Tract Infections in Women: Results of a Pilot Study. Eur Urol. 2016 Dec;70(6):912-915. PubMed: 27283213

57.Barea BM, Veeratterapillay R, Harding C. Nonantibiotic treatments for urinary cystitis: an update. Curr Opin Urol. 2020 Nov;30(6):845-852. PubMed: 33009152

58.Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79-84. PubMed: 23633128

59.Faustino M, Silva S, Costa EM, Pereira AM, Pereira JO, Oliveira AS, Ferreira CMH, Pereira CF, Durão J, Pintado ME, Carvalho AP. Effect of Mannan Oligosaccharides Extracts in Uropathogenic Escherichia coli Adhesion in Human Bladder Cells. Pathogens. 2023 Jun 28;12(7) PMC free article: PMC10384913 PubMed: 37513732

60.Salvatore S, Ruffolo AF, Stabile G, Casiraghi A, Zito G, De Seta F. A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections. Eur Urol Focus. 2023 Jul;9(4):654-659. PubMed: 36621376

61.Wagenlehner F, Lorenz H, Ewald O, Gerke P. Why d-Mannose May Be as Efficient as Antibiotics in the Treatment of Acute Uncomplicated Lower Urinary Tract Infections-Preliminary Considerations and Conclusions from a Non-Interventional Study. Antibiotics (Basel). 2022 Feb 25;11(3) PMC free article: PMC8944421 PubMed: 35326777

62.Parazzini F, Ricci E, Fedele F, Chiaffarino F, Esposito G, Cipriani S. Systematic review of the effect of D-mannose with or without other drugs in the treatment of symptoms of urinary tract infections/cystitis (Review). Biomed Rep. 2022 Aug;17(2):69. PMC free article: PMC9260159 PubMed: 35815191

63.Lenger SM, Chu CM, Ghetti C, Durkin MJ, Jennings Z, Wan F, Sutcliffe S, Lowder JL. d-Mannose for Recurrent Urinary Tract Infection Prevention in Postmenopausal Women Using Vaginal Estrogen: A Randomized Controlled Trial. Urogynecology (Phila). 2023 Mar 01;29(3):367-377. PubMed: 36808931

64.Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES. Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial. Female Pelvic Med Reconstr Surg. 2021 Feb 01;27(2):112-117. PubMed: 31232721

65.Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, Lotan Y. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med. 2018 Nov 01;178(11):1509-1515. PMC free article: PMC6584323 PubMed: 30285042

66.Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;2004(3):CD001209. PMC free article: PMC7032641 PubMed: 15266443

67.Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and Prevention of Recurrent Lower Urinary Tract Infections in Women: A Rapid Review with Practice Recommendations. J Urol. 2018 Dec;200(6):1174-1191. PubMed: 29940246

68.Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis. 1988 Jun;157(6):1239-42. PubMed: 3259613

69.Nicolle LE, Ronald AR. Recurrent urinary tract infection in adult women: diagnosis and treatment. Infect Dis Clin North Am. 1987 Dec;1(4):793-806. PubMed: 3333659

70.Liu Y, Xiao D, Shi XH. Urinary tract infection control in intensive care patients. Medicine (Baltimore). 2018 Sep;97(38):e12195. PMC free article: PMC6160021 PubMed: 30235665

71.Li F, Song M, Xu L, Deng B, Zhu S, Li X. Risk factors for catheter-associated urinary tract infection among hospitalized patients: A systematic review and meta-analysis of observational studies. J Adv Nurs. 2019 Mar;75(3):517-527. PubMed: 30259542

72.Lengetti E, Kronk R, Ulmer KW, Wilf K, Murphy D, Rosanelli M, Taylor A. An innovative approach to educating nurses to clinical competence: A randomized controlled trial. Nurse Educ Pract. 2018 Nov;33:159-163. PubMed: 30253916

73.Vachhani AV, Barvaliya M, Naik V, Jha P, Tripathi C. Effectiveness and tolerability of short course co-trimoxazole, norfloxacin and levofloxacin in bacteriological cure of uncomplicated urinary tract infection in outpatient setting. An open label, parallel group, randomized controlled trial. Infez Med. 2015 Jun;23(2):155-60. PubMed: 26110296

74.Duane S, Beecher C, Vellinga A, Murphy AW, Cormican M, Smyth A, Healy P, Moore M, Little P, Devane D. A systematic review of the outcomes reported in the treatment of uncomplicated urinary tract infection clinical trials. JAC Antimicrob Resist. 2022 Apr;4(2):dlac025. PMC free article: PMC8944192 PubMed: 35350132

75.Lodise TP, Henriksen AS, Hadley T, Patel N. US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales. Open Forum Infect Dis. 2021 Oct;8(10):ofab380. PMC free article: PMC8516593 PubMed: 34660834

76.Fuchs F, Hamprecht A. Results from a Prospective In Vitro Study on the Mecillinam (Amdinocillin) Susceptibility of Enterobacterales. Antimicrob Agents Chemother. 2019 Apr;63(4) PMC free article: PMC6437539 PubMed: 30917983

77.Kahlmeter G, Åhman J, Matuschek E. Antimicrobial Resistance of Escherichia coli Causing Uncomplicated Urinary Tract Infections: A European Update for 2014 and Comparison with 2000 and 2008. Infect Dis Ther. 2015 Dec;4(4):417-23. PMC free article: PMC4675763 PubMed: 26507395

78.Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. Int J Antimicrob Agents. 2012 Jan;39(1):45-51. PubMed: 22055529

79.Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE., Infectious Diseases Society of America. European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 01;52(5):e103-20. PubMed: 21292654

80.Dahash BA, Sankararaman S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 7, 2023. Carnitine Deficiency. PubMed: 32644467

81.Jansåker F, Thønnings S, Hertz FB, Kallemose T, Værnet J, Bjerrum L, Benfield T, Frimodt-Møller N, Knudsen JD. Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial. EClinicalMedicine. 2019 Jul;12:62-69. PMC free article: PMC6677655 PubMed: 31388664

82.Jodal U, Larsson P, Hansson S, Bauer CA. Pivmecillinam in long-term prophylaxis to girls with recurrent urinary tract infection. Scand J Infect Dis. 1989;21(3):299-302. PubMed: 2756342

83.Bollestad M, Grude N, Solhaug S, Raffelsberger N, Handal N, Nilsen HS, Romstad MR, Emmert A, Tveten Y, Søraas A, Jenum PA, Jenum S, Møller-Stray J, Weme ET, Lindbaek M, Simonsen GS., (the Norwegian ESBL UTI study group). Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. J Antimicrob Chemother. 2018 Sep 01;73(9):2503-2509. PubMed: 29982514

84.Jansåker F, Frimodt-Møller N, Sjögren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother. 2014 Mar;69(3):769-72. PubMed: 24107388